For years, venture capital (VC) firms were considered relatively benign risks in the directors and officers (D&O) insurance market.
Compared to traditional buyout private equity, VCs generated fewer claims, fewer losses, and generally enjoyed broad coverage, healthy capacity, and competitive pricing. READ MORE
